WordNet

(medicine) the act of caring for someone (as by medication or remedial training etc.); "the quarterback is undergoing treatment for a knee injury"; "he tried every treatment the doctors suggested"; "heat therapy gave the best relief"
the secretion of an endocrine gland that is transmitted by the blood to the tissue on which it has a specific effect (同)endocrine, internal_secretion

PrepTutorEJDIC

(病気の)治療,療法 / =psychotherapy
ホルモン

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 転移性ホルモン受容体陽性乳癌に対する治療アプローチ：内分泌療法 treatment approach to metastatic hormone receptor positive breast cancer endocrine therapy
2. 閉経期のホルモン療法で用いる製剤 preparations for menopausal hormone therapy
3. 非転移性ホルモン受容体陽性乳癌に対する補助内分泌療法 adjuvant endocrine therapy for non metastatic hormone receptor positive breast cancer
4. 性腺刺激ホルモン放出ホルモン単独欠乏症（特発性低ゴナドトロピン性性腺機能低下症） isolated gonadotropin releasing hormone deficiency idiopathic hypogonadotropic hypogonadism
5. ホルモン療法を用いた閉経期症状の治療 treatment of menopausal symptoms with hormone therapy

English Journal

Endometriosis: pathogenesis and treatment.

Vercellini P1, Viganò P2, Somigliana E1, Fedele L1.Author information 1Department of Obstetrics and Gynecology, Fondazione Cà Granda, Ospedale Maggiore Policlinico, Via Commenda 12, 20122 Milan, Italy.2Reproductive Sciences Laboratory, Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Via Olgettina 60, 20136 Milan, Italy.AbstractEndometriosis is defined as the presence of endometrial-type mucosa outside the uterine cavity. Of the proposed pathogenic theories (retrograde menstruation, coelomic metaplasia and Müllerian remnants), none explain all the different types of endometriosis. According to the most convincing model, the retrograde menstruation hypothesis, endometrial fragments reaching the pelvis via transtubal retrograde flow, implant onto the peritoneum and abdominal organs, proliferate and cause chronic inflammation with formation of adhesions. The number and amount of menstrual flows together with genetic and environmental factors determines the degree of phenotypic expression of the disease. Endometriosis is estrogen-dependent, manifests during reproductive years and is associated with pain and infertility. Dysmenorrhoea, deep dyspareunia, dyschezia and dysuria are the most frequently reported symptoms. Standard diagnosis is carried out by direct visualization and histologic examination of lesions. Pain can be treated by excising peritoneal implants, deep nodules and ovarian cysts, or inducing lesion suppression by abolishing ovulation and menstruation through hormonal manipulation with progestins, oral contraceptives and gonadotropin-releasing hormone agonists. Medical therapy is symptomatic, not cytoreductive; surgery is associated with high recurrence rates. Although lesion eradication is considered a fertility-enhancing procedure, the benefit on reproductive performance is moderate. Assisted reproductive technologies constitute a valid alternative. Endometriosis is associated with a 50% increase in the risk of epithelial ovarian cancer, but preventive interventions are feasible.
Nature reviews. Endocrinology.Nat Rev Endocrinol.2014 May;10(5):261-75. doi: 10.1038/nrendo.2013.255. Epub 2013 Dec 24.
Endometriosis is defined as the presence of endometrial-type mucosa outside the uterine cavity. Of the proposed pathogenic theories (retrograde menstruation, coelomic metaplasia and Müllerian remnants), none explain all the different types of endometriosis. According to the most convincing model, t
PMID 24366116

Degarelix: A Review of Its Use in Patients with Prostate Cancer.

Carter NJ1, Keam SJ.Author information 1Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand, demail@springer.com.AbstractDegarelix (Firmagon®; Gonax®) is a gonadotropin-releasing hormone receptor antagonist that is approved for the treatment of advanced (hormone-dependent) prostate cancer in the US and EU and the treatment of prostate cancer in Japan. In a pivotal randomized, controlled, 12-month phase III study, degarelix (initial subcutaneous dose of 240 mg followed by monthly dosages of 80 mg) was noninferior to leuprolide (monthly intramuscular dosages of 7.5 mg) in patients with prostate cancer of any stage for which endocrine treatment was indicated (except neoadjuvant hormonal therapy) with regard to suppression of testosterone to castration levels (i.e. ≤0.5 ng/mL). Suppression of testosterone and prostate-specific antigen (PSA) levels was faster with degarelix than with leuprolide, and no testosterone surges or microsurges were seen in degarelix recipients. Suppression of testosterone and PSA levels was maintained for the 12-month study duration and continued for up to 5 years in an extension to the main trial (including in patients switching from leuprolide to degarelix in the extension). The drug was generally well tolerated, with most adverse events being mild to moderate in severity. Injection-site reactions and events reflecting the expected effects of testosterone suppression (e.g. hot flushes, weight increase) were the most common treatment-emergent adverse events. Thus, degarelix is a useful option for the treatment of prostate cancer in patients for whom endocrine treatment is indicated.
Drugs.Drugs.2014 Apr 23. [Epub ahead of print]
Degarelix (Firmagon®; Gonax®) is a gonadotropin-releasing hormone receptor antagonist that is approved for the treatment of advanced (hormone-dependent) prostate cancer in the US and EU and the treatment of prostate cancer in Japan. In a pivotal randomized, controlled, 12-month phase III study, de
PMID 24756432

Follicle-stimulating hormone synthesis and fertility depend on SMAD4 and FOXL2.

Fortin J1, Boehm U, Deng CX, Treier M, Bernard DJ.Author information 1*Department of Pharmacology and Therapeutics, McGill University, Montréal, Québec, Canada;AbstractFollicle-stimulating hormone (FSH) is an essential regulator of gonadal function and fertility. Loss-of-function mutations in the FSHB/Fshb gene cause hypogonadotropic hypogonadism in humans and mice. Both gonadotropin-releasing hormone (GnRH) and activins, members of the transforming growth factor β (TGFβ) superfamily, stimulate FSH synthesis; yet, their relative roles and mechanisms of action in vivo are unknown. Here, using conditional gene-targeting, we show that the canonical mediator of TGFβ superfamily signaling, SMAD4, is absolutely required for normal FSH synthesis in both male and female mice. Moreover, when the Smad4 gene is ablated in combination with its DNA binding cofactor Foxl2 in gonadotrope cells, mice make essentially no FSH and females are sterile. Indeed, the phenotype of these animals is remarkably similar to that of Fshb-knockout mice. Not only do these results establish SMAD4 and FOXL2 as essential master regulators of Fshb transcription in vivo, they also suggest that activins, or related ligands, could play more important roles in FSH synthesis than GnRH.-Fortin, J., Boehm, U., Deng, C.-X., Treier, M., Bernard, D. J. Follicle-stimulating hormone synthesis and fertility depend on SMAD4 and FOXL2.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology.FASEB J.2014 Apr 16. [Epub ahead of print]
Follicle-stimulating hormone (FSH) is an essential regulator of gonadal function and fertility. Loss-of-function mutations in the FSHB/Fshb gene cause hypogonadotropic hypogonadism in humans and mice. Both gonadotropin-releasing hormone (GnRH) and activins, members of the transforming growth factor
PMID 24739304

Japanese Journal

Progression of Intracranial Meningioma during Luteinizing Hormone-Releasing Hormone Agonist Treatment for Prostate Cancer: Case Report

ANDA Takeo,HONDA Masaru,ISHIHARA Tokuhiro,KAMEI Toshiaki
Neurologia medico-chirurgica 54(4), 327-330, 2014
… The authors describe a male patient who developed a large intracranial meningioma during the hormone therapy for pre-existing prostate cancer. … Leuprorelin acetate, a luteinizing hormone-releasing hormone (LH-RH) agonist, was subsequently administered to the patient once a month for 3 years. …
NAID 130003383239

特別講演(第142回東邦医学会例会) 前立腺癌に対するホルモン療法のパラダイム・シフト

鈴木啓悦
東邦医学会雑誌 = Journal of Medical Society of Toho University 60(4), 204-212, 2013-07
… した．以来70年にわたり，前立腺癌に対するホルモン療法の基本的な概念は変わっていない．しかしながら，外科的精巣摘除術のみであったホルモン療法も，徐放性luteinizing hormone-releasing hormone（LH-RH）アゴニストやアンチアンドロゲン剤などの開発などが進み，間欠的ホルモン療法やcombined androgen blockade（CAB）療法など多様な選択肢が用意されてきた．ホルモ …
NAID 120005318030

内分泌療法で治療した尿管子宮内膜症の1例

三上穣太郎,山本勇人,岡本亜希子 [他],石村大史,今井篤,畠山真吾,米山高弘,橋本安弘,古家琢也,大山力
泌尿器科紀要 = Acta urologica Japonica 59(7), 431-434, 2013-07
… Administration of luteinizing hormone-releasing hormone agonist for 6 months markedly improved the hydronephrosis. … The patient received hormonal therapy for 2 years in total. … At present, there is no evidence of disease recurrence 6 months after the termination of hormonal therapy. …
NAID 120005308135